Insight

Guru Sonpavde: ctDNA for Evaluating Minimal Residual Disease in Bladder Cancer

Photo of Guru P. Sonpavde adventhealthcancerinstitute.com

Jun 22, 2024, 02:24

Guru Sonpavde: ctDNA for Evaluating Minimal Residual Disease in Bladder Cancer

Guru Sonpavde, Phase I and GU Oncology Director at Advent Health Cancer Institute, posted on LinkedIn:

“Circulating tumor (ct)-DNA for evaluating MRD (molecular/minimal residual disease) in bladder cancer: In this editorial European Urology, we discuss tumor-informed ctDNA:
1) based on whole-exome sequencing of the tumor,
2) based on whole genome sequencing (WGS) of the tumor and
3) a novel strategy using WGS of tumor and peripheral blood mononuclear cells with subsequent bioinformatics analyses for potentially more accurate ctDNA detection Lars Dyrskjøt Iver Nordentoft – pleased to coauthor from AdventHealth Central Florida cancer Institute– editorial led by Jason Brown– with coauthor Pedro C Barata, MD MSc FACP Lake Health/University Hospital Seidman Cancer Center.”

Visit the article website.
Source: Guru Sonpavde/LinkedIn

Advent Health Central Florida bioinformatics analyses bladder cancer Cancer research ctDNA detection editorial european urology Guru Sonpavde Iver Nordentoft Jason Brown Lake Health Lars Dyrskjøt Minimal Residual Disease MRD OncoDaily Oncology Pedro C Barata tumor-informed ctDNA University Hospital Seidman Cancer Center. WGS whole genome sequencing

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage